buyModerate cluster of 3

Samuel J Reich bought $9,842 of SABS

Executive Chairman at SAB Biotherapeutics, Inc.. 11,000 shares at an average of $0.89, traded Nov 29, 2023, filed Nov 30, 2023.

Conviction score

Value

$9,842

11,000 shares

Holdings after

219,001

+5% from before

From 52-week low

+129%

low $3.80, close $8.70

From 52-week high

-23%

high $11.30, as of Nov 29, 2023

Score components

Role
Chair
+20
Trade size
$10k at market
0
Relative to holdings
Holdings up 5%
+3
Price context
23% below the 52-week high
+4
Cluster
3 insiders buying within 14 days
+15
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -29.2%, 3m -54.1%, 6m -72.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

SABSOct 12, 2026 · close 2.83

Since filing Nov 30, 2023: -70.9%SPY +76.8% · excess -147.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000950170-23-066901, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Nov 29, 2023	POpen-market purchase Common Stock	+11,000	$0.89	$9,842	219,001	Nov 30, 2023

Related signals

Other insiders at SAB Biotherapeutics, Inc. and this insider’s other filings.

Score	Company	Insider	Value	Holdings	Filed
39Weak	SABSbuy 3 SAB Biotherapeutics, Inc.	Eddie Joe Sullivan Chief Executive Officer	$1,531 1,740 shares	+0%	Dec 8, 2023
45Moderate	SABSbuy 3 SAB Biotherapeutics, Inc.	Michael King CHIEF FINANCIAL OFFICER	$4,500 5,000 shares	-	Nov 30, 2023

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.